BACKGROUND: Recent data have suggested that insulin-requiring diabetes mostly contributes to the overall increase of thromboembolic risk in patients with atrial fibrillation (AF) on warfarin. We evaluated the prognostic role of a different diabetes status on clinical outcome in a large cohort of AF patients treated with edoxaban. METHODS: We accessed individual patients' data from the prospective, multicenter, ETNA-AF Europe Registry. We compared the rates of ischemic stroke/transient ischemic attack (TIA)/systemic embolism, myocardial infarction (MI), major bleeding and all-cause death at 2 years according to diabetes status. RESULTS: Out of an overall population of 13,133 patients, 2885 had diabetes (22.0%), 605 of whom (21.0%) were on insulin. The yearly incidence of ischemic stroke/TIA/systemic embolism was 0.86% in patients without diabetes, 0.87% in diabetic patients not receiving insulin (p = 0.92 vs no diabetes) and 1.81% in those on insulin (p = 0.002 vs no diabetes; p = 0.014 vs diabetes not on insulin). The annual rates of MI and major bleeding were 0.40%, 0.43%, 1.04% and 0.90%, 1.10% and 1.71%, respectively. All-cause yearly mortality was 3.36%, 5.02% and 8.91%. At multivariate analysis, diabetes on insulin was associated with a higher rate of ischemic stroke/TIA/systemic embolism [adjusted HR 2.20, 95% CI 1.37-3.54, p = 0.0011 vs no diabetes + diabetes not on insulin] and all-cause death [aHR 2.13 (95% CI 1.68-2.68, p < 0.0001 vs no diabetes]. Diabetic patients not on insulin had a higher mortality [aHR 1.32 (1.11-1.57), p = 0.0015], but similar incidence of stroke/TIA/systemic embolism, MI and major bleeding, vs those without diabetes. CONCLUSIONS: In a real-world cohort of AF patients on edoxaban, diabetes requiring insulin therapy, rather than the presence of diabetes per se, appears to be an independent factor affecting the occurrence of thromboembolic events during follow-up. Regardless of the diabetes type, diabetic patients had a lower survival compared with those without diabetes.

Daiichi Sankyo Europe Munich Germany

Department of Cardiology University Heart and Vascular Centre UKE Hamburg Germany

Department of Translational Medicine Maggiore della Carità Hospital University of Eastern Piedmont Via Solaroli 17 28100 Novara Italy

Institute of Cardiovascular Sciences University of Birmingham SWBH and UHB NHS Trusts Birmingham UK

Institute of Computer Science of the Czech Academy of Sciences Prague Czech Republic

Medical Faculty Charles University Pilsen Czech Republic

The Atrial Fibrillation NETwork (AFNET Münster Germany

University Cardiology Division Cardiovascular and Thoracic Department Pisa University Hospital University of Pisa Via Paradisa 2 56124 Pisa Italy

Zobrazit více v PubMed

Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864. doi: 10.1001/jama.285.22.2864. PubMed DOI

Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J. 2010;31:2369–2429. doi: 10.1093/eurheartj/ehq278. PubMed DOI

Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, ESC Committee for Practice Guidelines (CPG) 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719–2747. doi: 10.1093/eurheartj/ehs253. PubMed DOI

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373–498. doi: 10.1093/eurheartj/ehaa612. PubMed DOI

Patti G, Lucerna M, Cavallari I, et al. Insulin-requiring versus noninsulin-requiring diabetes and thromboembolic risk in patients with atrial fibrillation. J Am Coll Cardiol. 2017;69:409–419. doi: 10.1016/j.jacc.2016.10.069. PubMed DOI

Targher G, Chonchol M, Zoppini G, Franchini M. Hemostatic disorders in type I diabetes mellitus. Semin Thromb Hemost. 2011;37:058–065. doi: 10.1055/s-0030-1270072. PubMed DOI

Patti G, Cerchiara E, Bressi E, et al. Endothelial dysfunction, fibrinolytic activity, and coagulation activity in patients with atrial fibrillation according to type II diabetes mellitus status. Am J Cardiol. 2020;125:751–758. doi: 10.1016/j.amjcard.2019.11.030. PubMed DOI

De Caterina R, Patti G, Westerbergh J, et al. Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the Aristotle trial. Eur Heart J-Cardiovasc Pharmacother. 2022;8:227–235. doi: 10.1093/ehjcvp/pvaa140. PubMed DOI

De Caterina R, Kelly P, Monteiro P, et al. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. J Cardiovasc Med. 2019;20:97–104. doi: 10.2459/JCM.0000000000000737. PubMed DOI

De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, Lopez-de-Sa E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Kerschnitzki M, Reimitz PE, Kirchhof P, On behalf of the ETNA-AF Europe investigators Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe) BMC Cardiovasc Disord. 2019;19:165. doi: 10.1186/s12872-019-1144-x. PubMed DOI PMC

de Groot JR, Weiss TW, Kelly P, et al. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-europe study. Eur Heart J-Cardiovasc Pharmaco. 2021;7:f30–f39. doi: 10.1093/ehjcvp/pvaa079. PubMed DOI PMC

Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104. doi: 10.1056/NEJMoa1310907. PubMed DOI

Lip GYH, Varughese GI. Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links. Int J Cardiol. 2005;105:319–321. doi: 10.1016/j.ijcard.2005.03.003. PubMed DOI

Patti G, Cavallari I, Andreotti F, et al. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nat Rev Cardiol. 2019;16:113–130. doi: 10.1038/s41569-018-0080-2. PubMed DOI PMC

Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case–control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011;108:56–62. doi: 10.1016/j.amjcard.2011.03.004. PubMed DOI PMC

Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–962. doi: 10.1016/S0140-6736(13)62343-0. PubMed DOI

Patti G, Di Gioia G, Cavallari I, Nenna A. Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: a study-level meta-analysis of phase III randomized trials. Diabetes Metab Res Rev. 2017;33:e2876. doi: 10.1002/dmrr.2876. PubMed DOI

Angiolillo DJ, Bernardo E, Sabaté M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2007;50:1541–1547. doi: 10.1016/j.jacc.2007.05.049. PubMed DOI

Khawand CE, Jamart J, Donckier J, et al. hemostasis variables in type I diabetic patients without demonstrable vascular complications. Diabetes Care. 1993;16:1137–1145. doi: 10.2337/diacare.16.8.1137. PubMed DOI

Carmassi F, Morale M, Puccetti R, et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res. 1992;67:643–654. doi: 10.1016/0049-3848(92)90068-L. PubMed DOI

Elhadd TA, Kennedy G, Hill A, et al. Abnormal markers of endothelial cell activation and oxidative stress in children, adolescents and young adults with type 1 diabetes with no clinical vascular disease. Diabetes Metab Res Rev. 1999;15:405–411. doi: 10.1002/(SICI)1520-7560(199911/12)15:6<405::AID-DMRR69>3.0.CO;2-H. PubMed DOI

Madonna R, De Caterina R. Cellular and molecular mechanisms of vascular injury in diabetes—Part I: pathways of vascular disease in diabetes. Vascul Pharmacol. 2011;54:68–74. doi: 10.1016/j.vph.2011.03.005. PubMed DOI

Madonna R, De Caterina R. Cellular and molecular mechanisms of vascular injury in diabetes—Part II: Cellular mechanisms and therapeutic targets. Vascul Pharmacol. 2011;54:75–79. doi: 10.1016/j.vph.2011.03.007. PubMed DOI

Spadaccio C, Patti G, De Marco F, et al. Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the prospective ARMYDA-AGEs study) Am J Cardiol. 2013;112:21–26. doi: 10.1016/j.amjcard.2013.02.046. PubMed DOI

Cosmi F, Shen L, Magnoli M, et al. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes: insulin treatment and prognosis in chronic hf. Eur J Heart Fail. 2018;20:888–895. doi: 10.1002/ejhf.1146. PubMed DOI

Shen L, Rørth R, Cosmi D, et al. Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. Eur J Heart Fail. 2019;21:974–984. doi: 10.1002/ejhf.1535. PubMed DOI PMC

Park K, Li Q, Evcimen ND, et al. Exogenous insulin infusion can decrease atherosclerosis in diabetic rodents by improving lipids, inflammation, and endothelial function. ATVB. 2018;38:92–101. doi: 10.1161/ATVBAHA.117.310291. PubMed DOI PMC

The ORIGIN Trial Investigators Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–328. doi: 10.1056/NEJMoa1203858. PubMed DOI

Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992. doi: 10.1056/NEJMoa1107039. PubMed DOI

Woerdeman J, van Duinkerken E, Wattjes MP, et al. Proliferative retinopathy in type 1 diabetes is associated with cerebral microbleeds, which is part of generalized microangiopathy. Diabetes Care. 2014;37:1165–1168. doi: 10.2337/dc13-1586. PubMed DOI

Cavallari I, Maddaloni E, Gragnano F, et al. Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. Intern Emerg Med. 2021;16:1583–1591. doi: 10.1007/s11739-021-02640-z. PubMed DOI

Patti G, Nusca A, Di Sciascio G. Meta-analysis comparison (nine trials) of outcomes with drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol. 2008;102:1328–1334. doi: 10.1016/j.amjcard.2008.07.012. PubMed DOI